JP5229221B2 - チェックポイント・キナーゼのインヒビターとしてのトリアゾロキナゾリノン誘導体 - Google Patents

チェックポイント・キナーゼのインヒビターとしてのトリアゾロキナゾリノン誘導体 Download PDF

Info

Publication number
JP5229221B2
JP5229221B2 JP2009507739A JP2009507739A JP5229221B2 JP 5229221 B2 JP5229221 B2 JP 5229221B2 JP 2009507739 A JP2009507739 A JP 2009507739A JP 2009507739 A JP2009507739 A JP 2009507739A JP 5229221 B2 JP5229221 B2 JP 5229221B2
Authority
JP
Japan
Prior art keywords
triazolo
isoquinolin
alkyl
heterocyclyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009507739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009535334A (ja
JP2009535334A5 (enExample
Inventor
アリントン，ケネス，エル
バーナディック，エドワード，ジェイ
ダドキン，バディム，ワイ
フラリー，マーク，イー
ヒャング，シャエイ，ワイ
ワン，チェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2009535334A publication Critical patent/JP2009535334A/ja
Publication of JP2009535334A5 publication Critical patent/JP2009535334A5/ja
Application granted granted Critical
Publication of JP5229221B2 publication Critical patent/JP5229221B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2009507739A 2006-04-25 2007-04-20 チェックポイント・キナーゼのインヒビターとしてのトリアゾロキナゾリノン誘導体 Expired - Fee Related JP5229221B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79469406P 2006-04-25 2006-04-25
US60/794,694 2006-04-25
PCT/US2007/009643 WO2007127138A1 (en) 2006-04-25 2007-04-20 Triazoloquinazolinone derivatives as inhibitors of checkpoint kinases

Publications (3)

Publication Number Publication Date
JP2009535334A JP2009535334A (ja) 2009-10-01
JP2009535334A5 JP2009535334A5 (enExample) 2010-10-14
JP5229221B2 true JP5229221B2 (ja) 2013-07-03

Family

ID=38441857

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009507739A Expired - Fee Related JP5229221B2 (ja) 2006-04-25 2007-04-20 チェックポイント・キナーゼのインヒビターとしてのトリアゾロキナゾリノン誘導体

Country Status (9)

Country Link
US (1) US7501435B2 (enExample)
EP (1) EP2013212A1 (enExample)
JP (1) JP5229221B2 (enExample)
AR (1) AR060619A1 (enExample)
AU (1) AU2007243520B2 (enExample)
CA (1) CA2649811A1 (enExample)
DO (1) DOP2007000082A (enExample)
TW (1) TW200806670A (enExample)
WO (1) WO2007127138A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102014902A (zh) * 2005-01-06 2011-04-13 默克公司 检查点激酶抑制剂
US7485649B2 (en) * 2005-01-06 2009-02-03 Merck & Co., Inc. Inhibitors of checkpoint kinases
CA2635361A1 (en) 2006-01-04 2007-07-19 Merck & Co., Inc. Inhibitors of checkpoint kinases
US9000027B2 (en) * 2008-02-04 2015-04-07 Dana-Farber Cancer Institute, Inc. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, bcl-2 and caspase-3
WO2009102537A1 (en) * 2008-02-14 2009-08-20 Merck & Co., Inc. Inhibitors of checkpoint kinases
WO2010104933A1 (en) 2009-03-11 2010-09-16 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2800819B1 (en) * 2012-01-06 2018-04-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Phosphorylation of histones and uses thereof
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
KR102875195B1 (ko) * 2019-04-03 2025-10-22 케미테라스, 인크. 티민 핵산 염기를 베이스로 하는 트리아졸로피리미딘류 및 그 제조 방법
TWI879771B (zh) 2019-06-06 2025-04-11 大陸商和記黃埔醫藥（上海）有限公司 三環類化合物及其用途
CN115197225B (zh) * 2021-09-03 2023-04-11 贵州大学 一种五元杂环并喹唑啉酮类化合物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1244501A (en) * 1968-03-09 1971-09-02 Aspro Nicholas Ltd Heterocyclic amines
PT760819E (pt) * 1994-05-24 2000-11-30 Hoffmann La Roche Derivado dicarbonilicos triciclicos
US5677309A (en) * 1996-03-22 1997-10-14 Neurogen Corporation 1,2,4-triazolo 4,3-c! quinazolin-3-ones and 1,2,4-triazolo 4,3-c!quinazolin-3-thiones; a new class of GABA brain receptor ligands
CA2519107A1 (en) * 2003-03-14 2004-09-23 Astrazeneca Ab Novel fused triazolones and the uses thereof
HRP20130429T1 (en) * 2005-06-10 2013-06-30 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CA2635361A1 (en) 2006-01-04 2007-07-19 Merck & Co., Inc. Inhibitors of checkpoint kinases

Also Published As

Publication number Publication date
CA2649811A1 (en) 2007-11-08
DOP2007000082A (es) 2007-12-31
US20070254879A1 (en) 2007-11-01
AU2007243520B2 (en) 2012-07-19
US7501435B2 (en) 2009-03-10
EP2013212A1 (en) 2009-01-14
WO2007127138A1 (en) 2007-11-08
JP2009535334A (ja) 2009-10-01
TW200806670A (en) 2008-02-01
AU2007243520A1 (en) 2007-11-08
AR060619A1 (es) 2008-07-02

Similar Documents

Publication Publication Date Title
JP5229221B2 (ja) チェックポイント・キナーゼのインヒビターとしてのトリアゾロキナゾリノン誘導体
JP4203121B1 (ja) チロシンキナーゼインヒビター
US20090233896A1 (en) Inhibitors of checkpoint kinases
JP2009525278A (ja) 脂肪酸シンターゼ（ｆａｓ）のインヒビター
JP2010512312A (ja) Ａｋｔ活性の阻害剤
US20090258852A1 (en) Inhibitors of Checkpoint Kinases
CA2714087A1 (en) Inhibitors of checkpoint kinases
US7550477B2 (en) Inhibitors of checkpoint kinases
JP2008526865A (ja) チェックポイントキナーゼの阻害剤
AU2006204072B2 (en) Inhibitors of checkpoint kinases
JP2009502791A (ja) チェックポイントキナーゼの阻害剤

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20090827

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090827

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100824

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120221

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20120314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121009

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20121009

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130109

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130205

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20130223

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130304

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160329

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees